The transcription factor peroxisome proliferator-activated receptor gamma (PPARγ), is a promising therapeutic target in animal models of stroke, traumatic brain injury, Alzheimer’s disease (AD) and Parkinson’s disease (PD), by maintaining BBB function and decreasing brain inflammation, oxidative stress and neuronal injury (Liu et al., 2018). Here, PPARG is linked to early-onset autosomal dominant Alzheimer disease.